LianBio Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for LianBio.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LianBio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:LIAN.Y - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2023	N/A	-88	-84	-84	N/A
6/30/2023	N/A	-86	-85	-84	N/A
3/31/2023	N/A	-107	-105	-104	N/A
12/31/2022	N/A	-110	-101	-99	N/A
9/30/2022	N/A	-113	-101	-99	N/A
6/30/2022	N/A	-104	-123	-122	N/A
3/31/2022	N/A	-162	-176	-175	N/A
12/31/2021	N/A	-196	-165	-164	N/A
9/30/2021	N/A	-188	-183	-182	N/A
6/30/2021	N/A	-295	-187	-186	N/A
3/31/2021	N/A	-198	-97	-97	N/A
12/31/2020	N/A	-140	-99	-98	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LIAN.Y's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if LIAN.Y's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if LIAN.Y's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LIAN.Y's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if LIAN.Y's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LIAN.Y's Return on Equity is forecast to be high in 3 years time

LianBio Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

Price target decreased to US$8.23

Price target increased to US$12.00

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies